Sleep Disorders: Sleep Disorders 1 |

A Propensity-Adjusted Comparative Analysis of PAP Adherence Associated With Use of Myair FREE TO VIEW

Maureen Crocker, BS; Sue Lynch, RN; Leslee Willes, MS; Colleen Kelly, PhD; Adam Benjafield, PhD
Author and Funding Information

ResMed Science Center, San Diego, CA

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):1269A. doi:10.1016/j.chest.2016.08.1383
Text Size: A A A
Published online

SESSION TITLE: Sleep Disorders 1

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Obstructive sleep apnea (OSA) is the most common form of sleep disordered breathing (SDB) and is highly prevalent in the US. First line therapy for OSA is continuous positive airway pressure (CPAP). Though proven to be an efficacious treatment, adherence to PAP therapy is an ongoing challenge for patients and healthcare providers. Patients who are undertreated risk having clinical complications as well as the potential of their therapy not being reimbursed. AirView is a cloud-based system, automatically receiving device data daily, allowing healthcare providers to manage patients with SDB. myAir is an online self-management program that syncs up with a patient’s PAP device and is designed to provide patients with personalized PAP therapy support. We conducted a retrospective, observational study to assess the impact of myAir on adherence to PAP treatment in patients with SDB. Adherence was evaluated for the first 90 days after PAP initiation, and adherence for patients who used myAir was compared to patients who did not use myAir

METHODS: The HIPAA-compliant myAir and AirView databases were queried to create a set of de-identified data records from patients with setup dates between October 1, 2014 and July 31, 2015 who use ResMed AirSense or AirCurve devices. These patients were identified as to whether they were users of myAir, and were excluded if the myAir activation date was more than 7 days later than the AirView therapy start date. To minimize risks of potential bias due to differences between the myAir and AirView-only groups that affect outcome variables, myAir and AirView-only patients were matched in a 1:2 ratio on propensity scores. A 25% random sample was drawn for analysis. This study protocol was IRB reviewed.

RESULTS: 952,819 patients were reviewed for inclusion and 588,369 patients met the inclusion/exclusion criteria, of which 42,679 used myAir and 545,690 were in AirView-only. For the primary analysis population, there were 10,670 myAir patients and 21,340 AirView-only patients matched on propensity scores Baseline characteristics were similar between the two groups (age, gender, device type, device mode, therapy initiation AHI). Patients in both groups were effectively treated with PAP therapy over the 90 days (mean residual AHI of myAir 2.7 vs AirView-only 3.2). All adherence endpoints were statistically and clinically significant in favor of myAir. There was a significant improvement in the percent of patients that reached Medicare adherence within 90 days (myAir 87.5% vs. AirView-only 70.3%, p <0.0001), showing an improvement in adherence of 17%. Additional outcomes include: the percent of patients that achieved adherence within the first 30 days of use (myAir 79.6% vs. AirView-only 59.6%, p <0.0001), mean daily PAP usage (5.9 vs 4.9 hrs, p <0.0001), and the percent of patients with use ≥4 hours/day (83.6% vs 66.2%, p <0.0001).

CONCLUSIONS: PAP adherence was significantly improved for patients that used the myAir application.

CLINICAL IMPLICATIONS: A sleep telehealth platform such as myAir provides an opportunity to improve PAP adherence in patients with SDB.

DISCLOSURE: Maureen Crocker: Employee: Medical Affairs employee of ResMed Corp Sue Lynch: Employee: Medical Affairs employee of ResMed LTd Leslee Willes: Other: Consultant of ResMed Corp Colleen Kelly: Other: Consultant of ResMed Corp Adam Benjafield: Employee: Medical Affairs employee of ResMed Corp

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543